Host: Jennifer Caudle, DO
Guest: Nan Chen, MD
Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.